Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market 2026 projected to reach $0.93 billion by 2030 at a CAGR of 9.2%

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market In 2026 And What Value Is Projected For 2030?

The warm autoimmune hemolytic anemia (WAIHA) treatment market has experienced significant expansion recently. Its size is expected to increase from $0.6 billion in 2025 to $0.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. Key drivers for this historical growth include a prevalent reliance on corticosteroid therapy, a limited array of treatment alternatives, the provision of autoimmune care primarily within hospitals, a dependency on blood transfusions, and an overall low level of disease awareness.

The warm autoimmune hemolytic anemia (waiha) treatment market size is projected to experience robust expansion in the coming years. It is anticipated to grow to $0.93 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.2%. The expansion during the forecast period is primarily driven by biologic drug innovation, enhanced autoimmune diagnostics, the increasing adoption of precision medicine, an expanding geriatric population, and the growth of specialty hematology care. Noteworthy trends for the forecast period include the increased utilization of monoclonal antibody therapies, a rising preference for steroid-sparing treatments, the broadening reach of personalized autoimmune therapies, the evolving role of IVIG in acute management, and advancements in diagnostic and monitoring protocols.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24426&type=smp

What Major Drivers Are Influencing Demand In The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

The rising healthcare expenditure is expected to stimulate the growth of the warm autoimmune hemolytic anemia (WAIHA) treatment market moving forward. Healthcare expenditure signifies the total financial outlay on health services, encompassing disease prevention, diagnosis, treatment, and management, by individuals, governments, and various organizations. Advances in medical technology are escalating healthcare expenditure, as newer diagnostic tools and treatments often involve higher costs for development, implementation, and ongoing patient care. This expenditure supports warm autoimmune hemolytic anemia (WAIHA) treatment by financing research, enabling access to advanced diagnostic tools, and ensuring the availability of specialized therapies that assist in managing and controlling the condition. For instance, in May 2024, data from the Office for National Statistics, a UK-based government agency, revealed that in real terms, long-term health and social care expenditures increased by 2.8% in 2022, but overall healthcare spending rose by 5.6% in 2023. Therefore, the expanding healthcare expenditure is driving the market growth for warm autoimmune hemolytic anemia (WAIHA) treatment.

What Are The Key Segments Of The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

The warm autoimmune hemolytic anemia (waiha) treatment market covered in this report is segmented –

1) By Treatment Type: Corticosteroids, Monoclonal Antibodies, Intravenous Immunoglobulin (IVIG), Blood Transfusions, Splenectomy

2) By Route Of Administration: Oral, Intravenous, Subcutaneous

3) By Patient Demographics: Children, Adults, Geriatric

4) By Therapeutic Area: Primary Autoimmune Disorders, Secondary Autoimmune Disorders, Genetic Predisposition

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone

2) By Monoclonal Antibodies: Rituximab, Sutimlimab, Bortezomib

3) By Intravenous Immunoglobulin: Standard IVIG, High-Dose IVIG Therapy, Pooled Plasma-Derived Immunoglobulins

4) By Blood Transfusions: Leukoreduced RBC Transfusions, Emergency Transfusions, Phenotypically Matched RBC Transfusions

5) By Splenectomy: Laparoscopic Splenectomy, Prophylactic Treatments Post-Splenectomy, Open Splenectomy

What Key Trends Are Influencing The Development Of The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

Leading companies in the warm autoimmune hemolytic anemia (WAIHA) treatment market are concentrating on creating novel solutions, such as monoclonal antibodies, to address existing clinical gaps and enhance patient results. Monoclonal antibodies are laboratory-developed proteins designed to target specific immune cells or pathways, thereby diminishing the destruction of red blood cells in warm autoimmune hemolytic anemia. For example, in July 2023, IASO Biotechnology, a biopharmaceutical firm based in China, declared that its IASO-782 Injection received approval from the U.S. Food and Drug Administration (FDA) for use in clinical studies within the United States for autoimmune hematological conditions, including warm autoimmune hemolytic anemia (WAIHA) and primary immune thrombocytopenia (ITP). This fully human monoclonal antibody targets CD19 and incorporates Fc mutations to boost ADCC activity while preserving other Fc functions. It specifically eliminates CD19+ B cells, plasma blasts, and certain plasma cells, which are responsible for generating auto-reactive antibodies. Given its unique mechanism, IASO-782 holds potential for treating autoimmune conditions stemming from pathogenic B and plasma cells, such as ITP and AIHA.

Who Are The Leading Companies Operating In The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

Major companies operating in the warm autoimmune hemolytic anemia (waiha) treatment market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Agios Pharmaceuticals Inc., Incyte Corporation, Mallinckrodt Pharmaceuticals, Xencor Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Immunovant Inc., Zenas BioPharma Inc., Alexion Pharmaceuticals Inc., CSL Behring, Grifols S.A., Octapharma AG, Kedrion Biopharma, LFB Group, ADMA Biologics Inc., Pfizer Inc., Bristol-Myers Squibb Company, Amgen Inc.

Read the full warm autoimmune hemolytic anemia (waiha) treatment market report here:

https://www.thebusinessresearchcompany.com/report/warm-autoimmune-hemolytic-anemia-waiha-treatment-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

North America was the largest region in the warm autoimmune hemolytic anemia (WAIHA) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the warm autoimmune hemolytic anemia (waiha) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24426&type=smp

Browse Through More Reports Similar to the Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market 2026, By The Business Research Company

Autoimmune Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Anemia And Other Blood Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Hemostasis Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemostasis-products-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info